Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This randomized trial will enroll adult recipients of HLA-identical living kidney transplants
who are at least 1 year post-transplant. All subjects will be taking Prograf (tacrolimus) or
cyclosporine and mycophenolic acid (CellCept or Myfortic) and then be randomized (1:2) to
either continue calcineurin inhibitors or to taper off of calcineurin inhibitors. The
hypothesis is that mycophenolic acid monotherapy permits long-term rejection-free renal
allograft function in the absence of long-term calcineurin inhibitors in this fully matched
renal transplant cohort.